24.40p
0.00%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About EKF Diagnostics Holdings
Its shares trade on LSE under the ticker EKF.L. It has been listed since 5 June 2002. In the fiscal year to 31 December 2025, it reported revenue of £51.6m and net income of £2.1m. At that date it held total assets of £81.1m and shareholders' equity of £69.0m.
EKF Diagnostics Holdings Plc is a vitro diagnostics company, which designs and manufactures diagnostic equipment for use within point-of-care settings. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2002-06-05. The firm manufactures and sells diagnostic instruments, reagents and certain ancillary products. The firm's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. The firm's Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen C-Line and Biosen S-Line, STAT-Site M B-HB analyzer, sTNFR1 biomarker test kits and Altair 240.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 5 Jun 2002
- Employees
- 309
- Website
- ekfdiagnostics.com ↗
Leadership
Pay as last reported
- Mr. Julian BainesExecutive Chairman of the Board, since 2009£278,000
- Mr. Gavin JonesChief Executive Officer, Executive Director, since 2025
- Mr. Stephen YoungChief Financial Officer, Executive Director, since 2023£225,000
- Mr. Christopher MillsNon-Executive Director£50,000
- Mr. Christian RiggSenior Independent Non-Executive Director£50,000
- Ms. Jennifer WinterIndependent Non-Executive Director£50,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 15
- Environment
- 20
- Social
- 22
- Governance
- 2
- Direct emissions (scope 1)
- 84 t
- Energy emissions (scope 2)
- 397 t
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- EKF Diagnostics Holdings PLC has a strong reputation in the medical diagnostics industry, recognized for its high-quality products and technology.
- The company has a diverse product portfolio with a wide range of diagnostic tests, catering to various healthcare needs.
- EKF Diagnostics Holdings PLC has established strong partnerships with healthcare providers and distributors, helping to expand its market presence globally.
Weaknesses
- The company heavily relies on third-party suppliers for its raw materials and components, making it vulnerable to supply chain disruptions and price fluctuations.
- EKF Diagnostics Holdings PLC may face challenges in the form of regulatory approvals and compliance requirements, particularly in different regions and jurisdictions.
- Limited market penetration in certain geographical areas or specific healthcare segments may restrict the company's growth potential.
Opportunities
- The growing demand for point-of-care diagnostic testing presents an opportunity for EKF Diagnostics Holdings PLC to expand its product offerings and reach a larger customer base.
- Advancements in medical technology and increased healthcare spending create opportunities for the company to innovate and develop new diagnostic solutions.
- Expansion into emerging markets, where healthcare infrastructure is developing, can provide EKF Diagnostics Holdings PLC with untapped growth prospects.
Threats
- Intense competition from other established players in the medical diagnostics industry poses a threat to EKF Diagnostics Holdings PLC's market share and pricing power.
- Changes in government regulations and reimbursement policies can impact the company's profitability and market access.
- Economic downturns and financial instability in key markets may lead to reduced healthcare spending and lower demand for diagnostic products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.